IHC further showed that, compared with the control, systemic and intranasal administration of LY294002, 3‐MA, and AS605240 significantly reduced the expression of p‐Akt and p‐mTOR in nasal polyps (Figure 2A–D). The gene discussed is MTOR; the disease is nasal cavity polyp.